China approves use of Roche arthritis drug for some Covid-19 patients


  • China
  • Wednesday, 04 Mar 2020

BEIJING (Reuters): China will use a Roche Holding AG arthritis drug to treat some coronavirus patients in severe condition, health authorities said on Wednesday (March 4), as the country seeks to build up treatment regimens to help the infected recover.

Tocilizumab, sold by the Swiss pharma giant under the trade name Actemra, can be prescribed to coronavirus patients who show serious lung damage and an elevated level of a protein called Interleukin 6, which could indicate inflammation or immunological diseases, the National Health Commission said in the latest version of its treatment guidelines published online.

Actemra can help contain inflammation related to Interleukin 6, according to Roche.

There is no clinical trial evidence yet that the drug will be effective on coronavirus patients, however. Actemra also has not received approval from China's National Medical Product Administration to be sold for use for coronavirus infections.

Chinese researchers recently registered a three-month clinical trial for Actemra that would recruit 188 coronavirus patients and take place from Feb 10 to May 10, according to records shown on China's clinical trials registration database.

Roche could not be immediately reached for comment. The firm said on Monday it donated 14 million yuan (S$2.8 million) worth of Actemra in February.

The firm said in January it expects sales and profits growth this year as demand for new drugs and more business in China offsets declines in older medicines whose patents have expired.

Chinese drugmakers have been racing to develop alternatives to Roche's treatment. Bio-Thera Solutions expects to file new drug approval for its Actemra biosimilar in 2021, and Zhejiang Hisun Pharmaceutical Co received in 2016 regulatory approval to conduct clinical trials for its Tocilizumab candidate, company filings showed.

Biosimilars are cheaper versions of complex biotech drugs such as Actemra. - Reuters

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights

China , Roche , covid-19 , arthritis , drug

   

Next In Regional

World Economic Forum to be held in Davos in January 2022
Philippines refuses to work with ICC 'war on drugs' probe
Covid-19: 18,815 new cases, Sarawak highest with 3,660 infections
Alibaba consolidates community group buying operations under new Taocaicai brand
China’s cyberspace watchdog presses Internet platforms to vet their online content as crackdown deepens
Dr Wee: Most travellers agree with the need for RTK-Antigen tests for safety’s sake
Asian shares fall on Chinese developers' woes
Japan cuts economic view on weaker production, spending due to Covid revival
HK stocks drop 2% to 2021 low on Evergrande contagion fears
Indonesia's Telkom to pursue IPO of unit in Q4, plans spinoffs

Stories You'll Enjoy


Vouchers